129 related articles for article (PubMed ID: 10873101)
1. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs.
Carpentier AF; Xie J; Mokhtari K; Delattre JY
Clin Cancer Res; 2000 Jun; 6(6):2469-73. PubMed ID: 10873101
[TBL] [Abstract][Full Text] [Related]
2. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice.
Carpentier AF; Chen L; Maltonti F; Delattre JY
Cancer Res; 1999 Nov; 59(21):5429-32. PubMed ID: 10554011
[TBL] [Abstract][Full Text] [Related]
3. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen.
Auf G; Carpentier AF; Chen L; Le Clanche C; Delattre JY
Clin Cancer Res; 2001 Nov; 7(11):3540-3. PubMed ID: 11705874
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors.
El Andaloussi A; Sonabend AM; Han Y; Lesniak MS
Glia; 2006 Nov; 54(6):526-35. PubMed ID: 16906541
[TBL] [Abstract][Full Text] [Related]
5. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
[TBL] [Abstract][Full Text] [Related]
6. Antimetastatic effect of CpG DNA mediated by type I IFN.
Hafner M; Zawatzky R; Hirtreiter C; Buurman WA; Echtenacher B; Hehlgans T; Männel DN
Cancer Res; 2001 Jul; 61(14):5523-8. PubMed ID: 11454702
[TBL] [Abstract][Full Text] [Related]
7. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
8. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides.
Baines J; Celis E
Clin Cancer Res; 2003 Jul; 9(7):2693-700. PubMed ID: 12855649
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
[TBL] [Abstract][Full Text] [Related]
10. Antitumor therapy with bacterial DNA and toxin: complete regression of established tumor induced by liposomal CpG oligodeoxynucleotides plus interleukin-13 cytotoxin.
Ishii KJ; Kawakami K; Gursel I; Conover J; Joshi BH; Klinman DM; Puri RK
Clin Cancer Res; 2003 Dec; 9(17):6516-22. PubMed ID: 14695156
[TBL] [Abstract][Full Text] [Related]
11. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy.
Mason KA; Ariga H; Neal R; Valdecanas D; Hunter N; Krieg AM; Whisnant JK; Milas L
Clin Cancer Res; 2005 Jan; 11(1):361-9. PubMed ID: 15671567
[TBL] [Abstract][Full Text] [Related]
12. Plasmidic CpG sequences induce tumor microenvironment modifications in a rat liver metastasis model.
Bertin S; Anjuere F; Gavelli A; Baque P; Soilihi BK; Brossette N; Loubat A; Pierrefite-Carle V
Int J Mol Med; 2008 Mar; 21(3):309-15. PubMed ID: 18288378
[TBL] [Abstract][Full Text] [Related]
13. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
14. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
[TBL] [Abstract][Full Text] [Related]
15. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.
Heckelsmiller K; Beck S; Rall K; Sipos B; Schlamp A; Tuma E; Rothenfusser S; Endres S; Hartmann G
Eur J Immunol; 2002 Nov; 32(11):3235-45. PubMed ID: 12555669
[TBL] [Abstract][Full Text] [Related]
16. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release.
Wang L; Jiang W; Ding G; Cao H; Lu Y; Luo P; Zhou H; Zheng J
Int Immunopharmacol; 2007 May; 7(5):646-55. PubMed ID: 17386412
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides.
Ishii KJ; Gursel I; Gursel M; Klinman DM
Curr Opin Mol Ther; 2004 Apr; 6(2):166-74. PubMed ID: 15195929
[TBL] [Abstract][Full Text] [Related]
18. Class C CpG oligodeoxynucleotides as a single agent and in combination with radiotherapy efficiently delayed growth of subcutaneous B16F1 tumors.
Cerkovnik P; Jezersek Novakovic B; Stegel V; Novakovic S
Innate Immun; 2009 Oct; 15(5):313-21. PubMed ID: 19723833
[TBL] [Abstract][Full Text] [Related]
19. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
20. Oligodeoxynucleotides containing CpG motifs can induce T cell-dependent arthritis in rats.
Svelander L; Erlandsson Harris H; Lorentzen JC; Trollmo C; Klareskog L; Bucht A
Arthritis Rheum; 2004 Jan; 50(1):297-304. PubMed ID: 14730628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
